Selected research
Market Outlook & Growth Opportunities
Global Preventive Vaccines Market Outlook and Growth Opportunities 2026
Market perspective
The global Preventive Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Preventive Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Preventive Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Preventive Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Preventive Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Preventive Vaccines market include Abbott, Sanofi, GlaxoSmithKline, AstraZeneca, Serum Institute of India and CSL Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Preventive Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Preventive Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Preventive Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Preventive Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.
Preventive Vaccines Segment by Company
Abbott
Sanofi
GlaxoSmithKline
AstraZeneca
Serum Institute of India
CSL Ltd
Preventive Vaccines Segment by Type
Intradermal Shot
Intramuscular Injection
Nasal Spray
Preventive Vaccines Segment by Application
Hospital
Clinic
Other
Preventive Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Preventive Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Preventive Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Preventive Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Preventive Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preventive Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Preventive Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preventive Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Preventive Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Preventive Vaccines industry.
Chapter 3: Detailed analysis of Preventive Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Preventive Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Preventive Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Intradermal Shot
- Intramuscular Injection
- Nasal Spray
Applications
- Hospital
- Clinic
- Other
Companies covered
- Abbott
- Sanofi
- GlaxoSmithKline
- AstraZeneca
- Serum Institute of India
- CSL Ltd
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Preventive Vaccines Sales Value (2021-2032)
- 1.2.2 Global Preventive Vaccines Sales Volume (2021-2032)
- 1.2.3 Global Preventive Vaccines Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Preventive Vaccines Market Dynamics
- 2.1 Preventive Vaccines Industry Trends
- 2.2 Preventive Vaccines Industry Drivers
- 2.3 Preventive Vaccines Industry Opportunities and Challenges
- 2.4 Preventive Vaccines Industry Restraints
3 Preventive Vaccines Market by Company
- 3.1 Global Preventive Vaccines Company Revenue Ranking in 2025
- 3.2 Global Preventive Vaccines Revenue by Company (2021-2026)
- 3.3 Global Preventive Vaccines Sales Volume by Company (2021-2026)
- 3.4 Global Preventive Vaccines Average Price by Company (2021-2026)
- 3.5 Global Preventive Vaccines Company Ranking (2024-2026)
- 3.6 Global Preventive Vaccines Company Manufacturing Base and Headquarters
- 3.7 Global Preventive Vaccines Company Product Type and Application
- 3.8 Global Preventive Vaccines Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Preventive Vaccines Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Preventive Vaccines Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Preventive Vaccines Market by Type
- 4.1 Preventive Vaccines Type Introduction
- 4.1.1 Intradermal Shot
- 4.1.2 Intramuscular Injection
- 4.1.3 Nasal Spray
- 4.2 Global Preventive Vaccines Sales Volume by Type
- 4.2.1 Global Preventive Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Preventive Vaccines Sales Volume by Type (2021-2032)
- 4.2.3 Global Preventive Vaccines Sales Volume Share by Type (2021-2032)
- 4.3 Global Preventive Vaccines Sales Value by Type
- 4.3.1 Global Preventive Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Preventive Vaccines Sales Value by Type (2021-2032)
- 4.3.3 Global Preventive Vaccines Sales Value Share by Type (2021-2032)
5 Preventive Vaccines Market by Application
- 5.1 Preventive Vaccines Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Preventive Vaccines Sales Volume by Application
- 5.2.1 Global Preventive Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Preventive Vaccines Sales Volume by Application (2021-2032)
- 5.2.3 Global Preventive Vaccines Sales Volume Share by Application (2021-2032)
- 5.3 Global Preventive Vaccines Sales Value by Application
- 5.3.1 Global Preventive Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Preventive Vaccines Sales Value by Application (2021-2032)
- 5.3.3 Global Preventive Vaccines Sales Value Share by Application (2021-2032)
6 Preventive Vaccines Regional Sales and Value Analysis
- 6.1 Global Preventive Vaccines Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Preventive Vaccines Sales by Region (2021-2032)
- 6.2.1 Global Preventive Vaccines Sales by Region: 2021-2026
- 6.2.2 Global Preventive Vaccines Sales by Region (2027-2032)
- 6.3 Global Preventive Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Preventive Vaccines Sales Value by Region (2021-2032)
- 6.4.1 Global Preventive Vaccines Sales Value by Region: 2021-2026
- 6.4.2 Global Preventive Vaccines Sales Value by Region (2027-2032)
- 6.5 Global Preventive Vaccines Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Preventive Vaccines Sales Value (2021-2032)
- 6.6.2 North America Preventive Vaccines Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Preventive Vaccines Sales Value (2021-2032)
- 6.7.2 Europe Preventive Vaccines Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Preventive Vaccines Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Preventive Vaccines Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Preventive Vaccines Sales Value (2021-2032)
- 6.9.2 South America Preventive Vaccines Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Preventive Vaccines Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Preventive Vaccines Sales Value Share by Country, 2025 VS 2032
7 Preventive Vaccines Country-level Sales and Value Analysis
- 7.1 Global Preventive Vaccines Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Preventive Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Preventive Vaccines Sales by Country (2021-2032)
- 7.3.1 Global Preventive Vaccines Sales by Country (2021-2026)
- 7.3.2 Global Preventive Vaccines Sales by Country (2027-2032)
- 7.4 Global Preventive Vaccines Sales Value by Country (2021-2032)
- 7.4.1 Global Preventive Vaccines Sales Value by Country (2021-2026)
- 7.4.2 Global Preventive Vaccines Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.9.2 France Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.16.2 China Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.19.2 India Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Preventive Vaccines Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Preventive Vaccines Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Preventive Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Abbott
- 8.1.1 Abbott Company Information
- 8.1.2 Abbott Business Overview
- 8.1.3 Abbott Preventive Vaccines Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Abbott Preventive Vaccines Product Portfolio
- 8.1.5 Abbott Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Preventive Vaccines Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Sanofi Preventive Vaccines Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 GlaxoSmithKline
- 8.3.1 GlaxoSmithKline Company Information
- 8.3.2 GlaxoSmithKline Business Overview
- 8.3.3 GlaxoSmithKline Preventive Vaccines Sales, Value and Gross Margin (2021-2026)
- 8.3.4 GlaxoSmithKline Preventive Vaccines Product Portfolio
- 8.3.5 GlaxoSmithKline Recent Developments
- 8.4 AstraZeneca
- 8.4.1 AstraZeneca Company Information
- 8.4.2 AstraZeneca Business Overview
- 8.4.3 AstraZeneca Preventive Vaccines Sales, Value and Gross Margin (2021-2026)
- 8.4.4 AstraZeneca Preventive Vaccines Product Portfolio
- 8.4.5 AstraZeneca Recent Developments
- 8.5 Serum Institute of India
- 8.5.1 Serum Institute of India Company Information
- 8.5.2 Serum Institute of India Business Overview
- 8.5.3 Serum Institute of India Preventive Vaccines Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Serum Institute of India Preventive Vaccines Product Portfolio
- 8.5.5 Serum Institute of India Recent Developments
- 8.6 CSL Ltd
- 8.6.1 CSL Ltd Company Information
- 8.6.2 CSL Ltd Business Overview
- 8.6.3 CSL Ltd Preventive Vaccines Sales, Value and Gross Margin (2021-2026)
- 8.6.4 CSL Ltd Preventive Vaccines Product Portfolio
- 8.6.5 CSL Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Preventive Vaccines Value Chain Analysis
- 9.1.1 Preventive Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Preventive Vaccines Sales Mode & Process
- 9.2 Preventive Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Preventive Vaccines Distributors
- 9.2.3 Preventive Vaccines Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst